How Analysts Feel About Alexion Pharmaceuticals Inc (NASDAQ:ALXN) After Decrease in Sellers?

March 17, 2018 - By Graig Alexander

 How Analysts Feel About Alexion Pharmaceuticals Inc (NASDAQ:ALXN) After Decrease in Sellers?

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.20, from 1.37 in 2017Q2. It turned negative, as 36 investors sold Alexion Pharmaceuticals, Inc. shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported.
Edge Wealth Mngmt Ltd Company holds 6,689 shares. The California-based Tcw Grp has invested 0.79% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Winslow Cap Mngmt Ltd Llc holds 0% or 17 shares in its portfolio. Bb&T holds 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 3,381 shares. Keybank National Association Oh owns 4,744 shares for 0% of their portfolio. Mitsubishi Ufj Tru And Corporation reported 447,478 shares stake. 3.19M are owned by Retail Bank Of New York Mellon Corp. Gabelli Funds Lc holds 11,200 shares. Suntrust Banks Incorporated has invested 0.02% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Victory invested in 0.04% or 121,142 shares. Alliancebernstein Lp invested in 0.05% or 515,592 shares. Dnb Asset Mngmt As holds 22,808 shares. Adage Cap Partners Gru Lc reported 385,698 shares or 0.13% of all its holdings. Adams Diversified Equity Fund Incorporated holds 73,400 shares. Calamos Ltd Liability reported 0.32% stake.

Since October 2, 2017, it had 0 buys, and 13 selling transactions for $4.63 million activity. 3,363 shares were sold by Moriarty John B, worth $389,099 on Tuesday, February 6. 2,553 shares were sold by HANTSON LUDWIG, worth $310,521. $76,805 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by Wagner Heidi L. $192,028 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Goff Brian. The insider Franchini Indrani Lall sold $169,696. Another trade for 6,079 shares valued at $707,048 was made by Clancy Paul J on Tuesday, February 6.

The stock of Alexion Pharmaceuticals Inc (NASDAQ:ALXN) registered a decrease of 7.81% in short interest. ALXN’s total short interest was 6.13M shares in March as published by FINRA. Its down 7.81% from 6.65M shares, reported previously. With 1.80 million shares average volume, it will take short sellers 3 days to cover their ALXN’s short positions. The short interest to Alexion Pharmaceuticals Inc’s float is 2.76%.

The stock decreased 0.06% or $0.08 during the last trading session, reaching $126.75. About 4.39 million shares traded or 107.23% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since March 17, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has market cap of $28.10 billion. The firm offers Soliris , a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It has a 64.34 P/E ratio. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 103 analyst reports since July 27, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of ALXN in report on Friday, October 20 with “Buy” rating. BMO Capital Markets maintained the shares of ALXN in report on Wednesday, September 13 with “Outperform” rating. The firm earned “Outperform” rating on Friday, March 16 by Credit Suisse. The rating was maintained by Jefferies with “Hold” on Thursday, July 27. RBC Capital Markets initiated the stock with “Outperform” rating in Wednesday, July 13 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Overweight” rating by JP Morgan on Monday, July 27. The firm has “Buy” rating given on Thursday, January 7 by Suntrust Robinson. The rating was upgraded by Morgan Stanley on Friday, October 2 to “Overweight”. The rating was maintained by SunTrust on Monday, February 12 with “Buy”. Jefferies maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, September 23 with “Hold” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.